• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Cannabis Industry Investor Presentations Now Available for On-Demand Viewing

    9/13/21 8:43:00 AM ET
    $CLVR
    $GNRS
    $IMCC
    $INCR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Business Services
    Finance
    Get the next $CLVR alert in real time by email

    Individual and institutional investors as well as advisors are invited to log-on to VirtualInvestorConferences.com to view the presentations

    NEW YORK, Sept. 13, 2021 /CNW/ - Virtual Investor Conferences® and KCSA Strategic Communications today announced that the presentations from the September 8th & 9th Cannabis Industry Virtual lnvestor Conference are now available for on-demand viewing at VirtualInvestorConferences.com.

    REGISTER OR LOGIN NOW AT:  https://bit.ly/3BUC6w8

    All presentations will be available for 24/7 on-demand replay for 90 days. Investors, advisors and analysts may also download shareholder materials from the "virtual trade booth" for the next three weeks.

    Presentations:

    Presenting Company

    Ticker(s)

    Innocan Pharma Corp.

    ((INNPF, CSE:INNO)

    MariMed Inc.

    OTCQX: MRMD

    The Valens Company Inc.

    ((VLNCF, TSX:VLNS)

    Nova Cannabis Inc.

    ((NVACF, TSX:NOVC)

    InMed Pharmaceuticals Inc.

    Nasdaq: INM

    Vibe Growth Corp.

    ((VIBEF, CSE:VIBE)

    1933 Industries Inc.

    OTCQB: TGIFF | CSE: TGIF

    MediPharm Labs Corp.

    ((MEDIF, TSX:LABS)

    IM Cannabis Corp.

    ((IMCC, CSE:IMCC)

    NewLake Capital Partners, Inc.

    OTCQX: NLCP

    Aleafia Health Inc.

    ((ALEAF, TSX:AH)

    InterCure Ltd.

    ((INCR, TSX:INCR)

    Verano Holdings Corp.

    ((VRNOF, CSE:VRNO)

    Fire & Flower Holdings Corp.

    ((FFLWF, TSX:FAF)

    Delta 9 Cannabis Inc,

    ((DLTNF, TSX:DN)

    Clever Leaves Holdings Inc.

    (NASDAQ: CLVR, CLVRW)

    Australis Capital Inc.

    ((AUSAF, CSE:AUSA)

    Lowell Farms Inc.

    ((LOWLF, CSE:LOWL)

    Flower One Holdings Inc.

    ((FLOOF, CSE:FONE)

    Sugarbud Craft Growers Corp.

    ((SBUDF, TSXV:SUGR)

    Greenrose Acquisition Corp.

    ((GNRS, GNRSU, GNRSW))

    To facilitate investor relations scheduling, for more information about the program and to view a complete calendar of Virtual Investor Conferences, please visit www.virtualinvestorconferences.com.

    About Virtual Investor ConferencesSM

    Virtual Investor Conferences (VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly-traded companies to meet and present directly with investors.



    A real-time solution for investor engagement, Virtual Investor Conferences is part of OTC Market Group's suite of investor relations services specifically designed for more efficient Investor Access.  Replicating the look and feel of on-site investor conferences, Virtual Investor Conferences combine leading-edge conferencing and investor communications capabilities with a comprehensive global investor audience network.

    SOURCE VirtualInvestorConferences.com

    Cision View original content: http://www.newswire.ca/en/releases/archive/September2021/13/c3553.html

    Get the next $CLVR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CLVR
    $GNRS
    $IMCC
    $INCR

    CompanyDatePrice TargetRatingAnalyst
    Intercure Ltd.
    $INCR
    5/18/2022$13.00Speculative Buy → Buy
    Canaccord Genuity
    Clever Leaves Holdings Inc.
    $CLVR
    12/23/2021$12.00 → $10.00Buy
    Canaccord Genuity
    InMed Pharmaceuticals Inc.
    $INM
    11/29/2021$6.00Buy
    HC Wainwright & Co.
    Clever Leaves Holdings Inc.
    $CLVR
    11/12/2021$13.00 → $12.00Buy
    Canaccord Genuity
    IM Cannabis Corp.
    $IMCC
    10/5/2021$8.00Buy
    ROTH Capital
    Clever Leaves Holdings Inc.
    $CLVR
    7/27/2021$13.00Buy
    Canaccord Genuity
    Clever Leaves Holdings Inc.
    $CLVR
    7/23/2021Market Perform
    Cowen
    IM Cannabis Corp.
    $IMCC
    7/14/2021Buy
    Desjardins
    More analyst ratings

    $CLVR
    $GNRS
    $IMCC
    $INCR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Hull Andrew

      4 - InMed Pharmaceuticals Inc. (0001728328) (Issuer)

      2/3/25 8:49:05 AM ET
      $INM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Sr VP & General Manager Johnson Shane Aaron

      4 - InMed Pharmaceuticals Inc. (0001728328) (Issuer)

      12/23/24 9:28:12 AM ET
      $INM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Financial Officer Jagpal Netta

      4 - InMed Pharmaceuticals Inc. (0001728328) (Issuer)

      12/23/24 9:26:50 AM ET
      $INM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLVR
    $GNRS
    $IMCC
    $INCR
    Financials

    Live finance-specific insights

    See more
    • IM Cannabis Reports First Quarter Financial Results

      IMC Delivers Net Profit and 87% Gross Margin Improvement in Q1, Reflecting Strategic and Operational Progress TORONTO and GLIL YAM, Israel, May 15, 2025 /PRNewswire/ -- IM Cannabis Corp. (the "Company" or "IMC") (NASDAQ:IMCC) (CSE:IMCC), an international medical cannabis company, announced its financial results today for the first quarter ended March 31, 2025. All amounts are reported in Canadian dollars and compared to the quarter ended March 31, 2024, unless otherwise stated. IMC also announces the intention to complete a non-brokered private placement of secured debentures. Q1 2025 Financial Highlights Net profit of $175K94% Gross profit increase vs. Q1 2024 of $3.5M vs. $1.8M and 29% Gr

      5/15/25 8:00:00 AM ET
      $IMCC
      Medicinal Chemicals and Botanical Products
      Health Care
    • IM Cannabis to Report First Quarter 2025 Financial Results on Thursday, May 15th at 9:00am ET

      TORONTO and GLIL YAM, Israel, May 6, 2025 /PRNewswire/ -- IM Cannabis Corp. (CSE:IMCC) (NASDAQ:IMCC) (the "Company", "IMCannabis", or "IMC"), a leading medical cannabis company with operations in Israel and Germany, will report operational and financial results for the first quarter 2025 ended March 31, 2025, on Thursday, May 15, 2025, before the market opens.     The Company will host a zoom web conference on the same day at 9:00am ET to discuss the results, followed by a question-and-answer session for the investment community. Investors are invited to register by clicking here. All relevant information will be sent upon registration. If you are unable to join us live, a recording of the

      5/6/25 7:00:00 AM ET
      $IMCC
      Medicinal Chemicals and Botanical Products
      Health Care
    • IM Cannabis Reports Fourth Quarter and Full Year 2024 Financial Results

      Q4 2024 Caps a Year of Strategic and Operational Improvements for IMC with 25% Revenue Growth, 42% decrease in Operating Expenses, and $0.5M Adjusted EBITDA Profit TORONTO and GLIL YAM, Israel, March 31, 2025 /PRNewswire/ -- IM Cannabis Corp. (the "Company" or "IMC") (NASDAQ:IMCC) (CSE:IMCC), an international medical cannabis company, is pleased to announce its financial results for the fourth quarter and year ended December 31, 2024. Unless otherwise stated, all amounts are reported in Canadian dollars and are compared to the quarter ended December 31, 2023. The Company's audited consolidated financial statements for the fiscal years ended December 31, 2024 and 2023 and accompanying manage

      3/31/25 8:39:00 AM ET
      $IMCC
      Medicinal Chemicals and Botanical Products
      Health Care

    $CLVR
    $GNRS
    $IMCC
    $INCR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • IM Cannabis Announces Plans to Voluntarily Delist from the Canadian Securities Exchange

      TORONTO and GLIL YAM, Israel, May 28, 2025 /PRNewswire/ -- IM Cannabis Corp. (the "Company" or "IMC") (NASDAQ:IMCC) (CSE:IMCC), an international medical cannabis company, announces that it has applied for a voluntary delisting of its common shares ("Shares") from the Canadian Securities Exchange (the "CSE"). The delisting from the CSE will not affect the Company's listing on NASDAQ and its Shares will continue trading on the NASDAQ under the symbol "IMCC". The Company is entertaining potential transactions that, if completed while the Company is listed on the CSE, would require the Company to incur unnecessary burdensome costs, approvals and delay. The Company believes that the trading volu

      5/28/25 8:00:00 AM ET
      $IMCC
      Medicinal Chemicals and Botanical Products
      Health Care
    • IM Cannabis Provides Corporate Updates

      THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES TORONTO and GLIL YAM, Israel, May 27, 2025 /PRNewswire/ -- IM Cannabis Corp. ("IM Cannabis" or the "Company") (NASDAQ:IMCC) (CSE:IMCC), a leading medical cannabis company with operations in Israel and Germany, is pleased to announce the following corporate updates. Meeting Results Further to its press releases dated Aprill 11, 2025 (the "April 11 Release") and May 7, 2025 (the "May 7 Release"), the Company is pleased to announce results of its annual general and special meeting, held on Friday, May 23, 2025 (the "Meeting"

      5/27/25 8:00:00 AM ET
      $IMCC
      Medicinal Chemicals and Botanical Products
      Health Care
    • IM Cannabis Reports First Quarter Financial Results

      IMC Delivers Net Profit and 87% Gross Margin Improvement in Q1, Reflecting Strategic and Operational Progress TORONTO and GLIL YAM, Israel, May 15, 2025 /PRNewswire/ -- IM Cannabis Corp. (the "Company" or "IMC") (NASDAQ:IMCC) (CSE:IMCC), an international medical cannabis company, announced its financial results today for the first quarter ended March 31, 2025. All amounts are reported in Canadian dollars and compared to the quarter ended March 31, 2024, unless otherwise stated. IMC also announces the intention to complete a non-brokered private placement of secured debentures. Q1 2025 Financial Highlights Net profit of $175K94% Gross profit increase vs. Q1 2024 of $3.5M vs. $1.8M and 29% Gr

      5/15/25 8:00:00 AM ET
      $IMCC
      Medicinal Chemicals and Botanical Products
      Health Care

    $CLVR
    $GNRS
    $IMCC
    $INCR
    SEC Filings

    See more
    • SEC Form DEFA14A filed by InMed Pharmaceuticals Inc.

      DEFA14A - InMed Pharmaceuticals Inc. (0001728328) (Filer)

      5/29/25 9:06:13 AM ET
      $INM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by IM Cannabis Corp.

      6-K - IM Cannabis Corp. (0001792030) (Filer)

      5/28/25 8:14:12 AM ET
      $IMCC
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 6-K filed by IM Cannabis Corp.

      6-K - IM Cannabis Corp. (0001792030) (Filer)

      5/27/25 8:11:41 AM ET
      $IMCC
      Medicinal Chemicals and Botanical Products
      Health Care

    $CLVR
    $GNRS
    $IMCC
    $INCR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • InterCure upgraded by Canaccord Genuity with a new price target

      Canaccord Genuity upgraded InterCure from Speculative Buy to Buy and set a new price target of $13.00

      5/18/22 7:21:05 AM ET
      $INCR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Canaccord Genuity reiterated coverage on Clever Leaves Holdings with a new price target

      Canaccord Genuity reiterated coverage of Clever Leaves Holdings with a rating of Buy and set a new price target of $10.00 from $12.00 previously

      12/23/21 7:40:56 AM ET
      $CLVR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. initiated coverage on InMed Pharmaceuticals with a new price target

      HC Wainwright & Co. initiated coverage of InMed Pharmaceuticals with a rating of Buy and set a new price target of $6.00

      11/29/21 6:20:24 AM ET
      $INM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLVR
    $GNRS
    $IMCC
    $INCR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by InMed Pharmaceuticals Inc.

      SC 13G/A - InMed Pharmaceuticals Inc. (0001728328) (Subject)

      11/14/24 4:36:01 PM ET
      $INM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by InMed Pharmaceuticals Inc.

      SC 13G - InMed Pharmaceuticals Inc. (0001728328) (Subject)

      11/12/24 1:44:16 PM ET
      $INM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Clever Leaves Holdings Inc. (Amendment)

      SC 13D/A - Clever Leaves Holdings Inc. (0001819615) (Subject)

      5/21/24 8:03:23 PM ET
      $CLVR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLVR
    $GNRS
    $IMCC
    $INCR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Hull Andrew bought $14,625 worth of shares (37,500 units at $0.39), increasing direct ownership by 4,947% to 38,258 units (SEC Form 4)

      4 - InMed Pharmaceuticals Inc. (0001728328) (Issuer)

      2/22/24 1:38:46 PM ET
      $INM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Adams Eric A bought $14,922 worth of shares (41,600 units at $0.36), increasing direct ownership by 1,763% to 43,959 units (SEC Form 4)

      4 - InMed Pharmaceuticals Inc. (0001728328) (Issuer)

      2/21/24 2:58:17 PM ET
      $INM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLVR
    $GNRS
    $IMCC
    $INCR
    Leadership Updates

    Live Leadership Updates

    See more
    • IM Cannabis Announces Appointment of Shmulik Arbel to Board of Directors

      TORONTO and GLIL YAM, Israel, Sept. 11, 2024 /PRNewswire/ --  IM Cannabis Corp. ("IMC" or the "Company") (NASDAQ:IMCC) (CSE:IMCC), a leading medical cannabis company with operations in Israel and Germany, is pleased to announce that Mr. Shmulik Arbel has been appointed to the Company's board of directors (the "Board") effective September 9, 2024. Mr. Arbel brings a wealth of experience in strategic plans that drive profitability, as well as, finance and corporate governance, further strengthening the company's commitment to driving growth while focusing on sustainable profitability. "We are thrilled to welcome Shmulik to our Board of Directors," said Oren Shuster, Chief Executive Officer of

      9/11/24 8:30:00 AM ET
      $IMCC
      Medicinal Chemicals and Botanical Products
      Health Care
    • IM Cannabis Announces the appointment of Uri Birenberg as Chief Financial Officer

      TORONTO and GLIL YAM, Israel, Oct. 10, 2023 /PRNewswire/ -- IM Cannabis Corp. (CSE:IMCC) (NASDAQ:IMCC) (the "Company", "IMCannabis", or "IMC"), a leading medical cannabis company with operations in Israel and Germany, is pleased to announce that Uri Birenberg will join the company's leadership team as Chief Financial Officer effective October 10, 2023.  This appointment strengthens IMC's financial leadership and strategic direction for achieving sustainable profitability. "We're delighted to welcome Uri as our new Chief Financial Officer at IMC. His impressive track record and extensive experience with large scale international organizations, as well as with startups, make him an outstandin

      10/10/23 7:00:00 AM ET
      $IMCC
      Medicinal Chemicals and Botanical Products
      Health Care
    • Clever Leaves Reminds Shareholders of its Upcoming Annual Meeting on June 2, 2023

      TOCANCIPÁ, Colombia, May 26, 2023 (GLOBE NEWSWIRE) -- Clever Leaves Holdings Inc. (NASDAQ:CLVR, CLVRW))) ("Clever Leaves" or the "Company"), a global medicinal cannabis company, reminds shareholders that it will hold its 2023 Annual Meeting of Shareholders (the "Annual Meeting") on Friday, June 2, 2023 at 10:00 a.m. Eastern Time. The Annual Meeting will be in a virtual-only format. Clever Leaves reminds investors that its board has recommended that shareholders vote "FOR" the proposal to elect each of the five (5) nominees named in the proxy statement to the Board of Directors, "FOR" the appointment of Marcum LLP as the Company's independent registered public accounting firm to serve as in

      5/26/23 8:30:00 AM ET
      $CLVR
      Biotechnology: Pharmaceutical Preparations
      Health Care